<SEC-DOCUMENT>0001213900-21-057891.txt : 20211110
<SEC-HEADER>0001213900-21-057891.hdr.sgml : 20211110
<ACCEPTANCE-DATETIME>20211109211847
ACCESSION NUMBER:		0001213900-21-057891
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20211110
FILED AS OF DATE:		20211110
DATE AS OF CHANGE:		20211109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		211394108

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea150323-6k_immuronlimited.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Month of November 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: 001-38104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>IMMURON LIMITED</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yes <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMURON LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron Limited (the &ldquo;Company&rdquo;) published one announcement
(the &ldquo;Public Notices&rdquo;) to the Australian Securities Exchange on November 10, 2021 titled:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: windings">-</FONT></TD><TD>&ldquo;US DoD Naval Medical Research Center Clinical Update&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of the Public Notice is attached as an
exhibit to this report on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 8%"><FONT STYLE="font-size: 10pt"><B>Exhibit</B><BR>
<B>Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; width: 91%; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><BR>
<B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea150323ex99-1_immuron.htm"><FONT STYLE="font-size: 10pt">US DoD Naval Medical Research Center Clinical Update</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><IMG SRC="image_001.jpg" ALT="" STYLE="width: 82px; height: 93px"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Date:&nbsp;&nbsp;November 10, 2021</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 37%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Company Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea150323ex99-1_immuron.htm
<DESCRIPTION>US DOD NAVAL MEDICAL RESEARCH CENTER CLINICAL UPDATE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>US
DoD Naval Medical Research Center Clinical Update</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key
Points</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manufacture
                                            of investigational medical products to support the US Naval Medical Research Centre (NMRC)
                                            clinical programs completed.</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IND
                                            submission to the U.S. Food and Drug administration (FDA) planned for Q1 CY2022 to support
                                            Two human phase II clinical trials.</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>One
                                            trial will focus on the ability of the hyperimmune product to prevent infectious diarrhea
                                            caused by ETEC and scheduled to be initiated H1 CY2022.</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
                                            second trial will focus on protecting volunteers against moderate to severe campylobacteriosis.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melbourne,
Australia, November 10, 2021: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing
and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today is pleased to provide shareholders
and the market with an update on the company&rsquo;s clinical development portfolio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company is pleased to inform shareholders that after facing over a 12-month hiatus due to the COVID-19 pandemic our clinical development
programs are back on track. The NMRC has reported that most of the inpatient clinical trial sites in the USA are coming off COVID-19
based restrictions and the Company looks forward to the recommencement of the planned NMRC clinical development programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this regard, the manufacturing campaign for the new drug product targeting <I>Campylobacter </I>and Enterotoxigenic <I>Escherichia coli
</I>(ETEC) was completed in October 2021. The investigational medical products will be transferred to the Johns Hopkins Bloomberg School
of Public Health (JHBSPH) in the USA, which is the clinical trial site to be used to conduct the two planned clinical studies. The safety
and protective efficacy of the product will be tested utilizing two controlled human infection-model clinical trials, with one trial
focusing on the ability of the hyperimmune product to protect volunteers against ETEC infections, and the second trial focusing on moderate
to severe campylobacteriosis. A total of 60 volunteers divided into two inpatient cohorts will be enrolled in the studies and randomly
assigned to either Cohort 1 ETEC or Cohort 2 <I>C. jejuni</I> controlled human infection models. Immuron is also pleased to report that
the NMRC is working on the Investigational New Drug (IND) application and the clinical protocols. The NMRC plans to file the IND application
with the U.S. Food and Drug administration (FDA) early in CY2022. The first of these exciting trials is scheduled to commence in the
first half of CY2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
release has been authorised by the directors of Immuron Limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
- - END - - -</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 3, 62 Lygon Street,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carlton South, Victoria</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AUSTRALIA &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3053</P></TD>
    <TD STYLE="width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>www.immuron.com</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ABN: 80 063 114 045</P></TD>
    <TD STYLE="width: 40%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Phone: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+ 61 (0)3 9824 5254</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Facsimile: + 61 (0)3 9822 7735</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><IMG SRC="ex99-1_002.jpg" ALT="">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-underline-color: black">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY
                                            CONTACT:</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr
    Jerry Kanellos, Ph.D.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph:
    +61 (0)3 9824 5254</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@immuron.com</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 37%; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Immuron</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology
platform with one commercial asset generating revenue. In Australia, Travelan&reg; is a listed medicine on the Australian Register of
Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers&rsquo; Diarrhea, reduce the risk of minor gastro-intestinal
disorders and is antimicrobial. In Canada, Travelan&reg; is a licenced natural health product (NPN 80046016) and is indicated to reduce
the risk of Travellers&rsquo; Diarrhea. In the U.S., Travelan&reg; is sold as a dietary supplement for digestive tract protection in
accordance with section 403 (r)(6) of the Federal Drug Administration (FDA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Travelan&reg;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travelan&reg;
is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers&rsquo; diarrhea,
a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan&reg; is a highly purified
tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria
and prevent colonization and the pathology associated with travelers&rsquo; diarrhea. In Australia, Travelan&reg; is a listed medicine
on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers&rsquo; Diarrhea, reduce
the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan&reg; is a licensed natural health product (NPN
80046016) and is indicated to reduce the risk of Travelers&rsquo; Diarrhea. In the U.S., Travelan&reg; is sold as a dietary supplement
for digestive tract protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Travelers&rsquo; diarrhea</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travelers&rsquo;
diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping,
bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic <I>Escherichia coli</I> (ETEC) playing
a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections
with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are
often confused with travelers&rsquo; diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information visit: http://www.immuron.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORWARD-LOOKING
STATEMENTS:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
press release may contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements
relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking
statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing
and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the
timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our
SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which
any such statement is based, except as required by law.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; font-size: 10pt; text-underline-color: black; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 33%; font-size: 10pt; text-underline-color: black; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 33%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Page 2 of 2</P></TD></TR>
  </TABLE>
<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !$ #P# 2(  A$! Q$!_\0
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M-EJ6E:G:3V&HZ?=P2826VO;.ZN;6XC?<CP32(Z,K$'<JO*2VY#T(VX& WS
MD$YYPQ ./J",T ?FG_P3]\0:Q\)H_B=^P'XWO]3O?%/[(-WHEK\'M7\0ZC)?
M^(/B3^Q;XW.I+^S9XZGU.94?Q!JW@:V\/^)/V>O'NIB);I_%OP>O-;OX85\4
MZ:US^AWBKQ-HG@WPYK'BOQ5JMCH7AKPQH^I:]XCU_5+A+73-%T?2+&6^U/5]
M0G?*6]G86L,US<2/\L<43L3@&OS=_P""B_A?Q+\)G^$__!0CX2^&=5\4?$C]
MB]]?N/B=X*T.-I-2^,7[&OQ"?2=+_:0\ S0VQBNM9UOX>:/I>C_M%_"_3'EN
M7N/'OPCM_#UC8W$7B_6+6[J?\%/?CMX4MO\ @E5^U=\7O#.NZ!XD\$?$;]FB
M>P^'7B.RNUDT/QC8?'^VTKP+\/KS2+Y0Z7%MXJD\?^'O[(N5B:W>75K(MPSJ
M #]2+*=+JVM[F*19(;BVMYHG1UD1XY8ED1U9>&#JP8.ORNK*0!5NL30;.+2M
M&TC35#*NGZ3IM@BLP8A;2S@MD!8!%W?($)*H&9<X&0!LJP894Y!Z$=P1D'CU
M!!'L><'B@!U-+@>XX!.1QD@#OGO4<TT42%I'15)*Y<@#(.#]X@$J03CKP:^&
MOVH_VXOAI^SQKFD?"K0/"WCC]HK]ISQEIBZQ\/?V6O@9I\'B#XJ>(]+,_E)X
MF\47=Y=Z=X.^$?PXMY(KB;4?B-\4?$'A?PTT>GWMMHEQK6NQQ:/. ?=&\8X(
M+<@#U8''J<#/J?QJA?ZC::=;O=:C=66GVT8!>YOKF*T@C."<F>X>*(;>2/G&
M!SD9K\E8/V?/^"F7[4NC0:A^T+^U/8_L(^#];2*Z?X!_L1Z7H7B_XL:%:*1>
MVUAXP_:[^*&CZO!<^(([A_L/B"#X7_"7P_H\BP20Z1XCN[:<WU=%H'_!&O\
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?",X)[?4' P44 2H %''.,9P,XZ 9^@ _ 4^BB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !2 10# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^N8F^(/A
MV"^>SDNW$Z2>4R^4WWLX]/6NGKYTU3_D<;O_ *_S_P"AUV83#QK.2ET1RXFM
M*DER]3Z+JCJFL6&BVAN=0N4@BZ L>6/H!U-7'=8XV=SA5!)/H*^>O$.LW?BK
MQ"TWSR!Y/*M81_"N<  >IZU.%PWMY.[LEN5B*_LHZ:MGI;_%G05FV+!>LF?O
MB,?RSFNGT7Q'I7B"$R:==+(5^_&?E=?J#7G5M\(;N2S#W.J1Q7)&?+6+<JGT
M)S7(7-MJW@SQ#M\SR+R'E)$Y5U/?W!]#75]5PU6\:,O>1S?6*].TJL=#VK7?
M&6B^'W\J\N=UQC/DQ#<_X^GXUB6OQ6T":8),EW;J?XWCR/QP:\U\/>&]2\7Z
ME/Y<H !WW%S+DX)_F370ZW\++W3=.DN[*]6\,2EGB,>UB!UV\G/TI_5L+!\E
M27O!]8Q$USPCH>N6EY;7]JES:3)-"XRKH<@U/7AWPZ\12Z3X@ALF<FRO6V,A
M/"N?NL/Y&O;II4MX))I#A(U+,?0 9-<6)P[HSY=^QU4*RJPYBGJVM:=H=K]H
MU&Z2"/HN>2Q] .IKDF^+.@B;:(+TQY^_Y8_EG->8ZQJE]XK\0F8AI))I/+MH
M1_"I/RJ/ZUV,/PANVLPTVJQI<D9V+%E0?3.<UV?5:%**]O+5G+]9K5)/V*T1
MZ-HWB#3-?@,NG72R[?OIT9/J#S5'7/&NB>'Y##=W)>X YAA7<P^O8?C7BTJ:
MOX-\0.BR&WO81C>G*NI'7W!JQX:\+:AXMO9S%*$C0[I[F7+?,>WN33^HTH_O
M)2]P7URI+W(Q]X])M/BKX?GF"3+=6P/\<D>5_'!-=I;74%[;)<6TR30N,JZ'
M((KQ[7OA?>Z5ITE[9W@O%B7=)'Y>UL#J1SS4/PT\13:;KT>F.Y-G>G:%)X23
ML1]>AJ*F%I3INI0>Q<,14C-0K+<]CU"_M]+T^:^NW*00KN=@,X'TK*T?QEHN
MO7IL]/N6DF"%]IC9>!]?K3/'/_(D:M_UP_J*\U^%1_XJ]O\ KV?^8K&CAXSH
M3J/=&M6M*-:,%LSVNHYYDMK>6>4D1QH78@9P ,FI*I:Q_P @2_\ ^O:3_P!!
M-<B5VD=+=E<R=+\<Z#K.H16-E=.\\N2JF)AG R>2*T=:U[3_  _:I<ZC*T<3
MOL!"EN<9[?2O%OAS_P COIW^Z_\ Z :[SXM_\BU:_P#7T/\ T$UWU<+".(C2
M6S_X)QT\1.5"51[HZ.R\7Z)?Z;<:C%>A;6W;;))(I4 XSCGK6-%\3]$N=3@L
MK:*[E,TBQK)Y8"Y)QGDYQ7CEM]MO5BTNV#R"6;<D"_Q/C&?RKT?1/A;<V=S:
MW]]J4<<D$BRF*--P&#G!8FM:F$P]&_M)>AG#$UJMN1>IZ3?7]IIEG)>7UQ';
MV\0W/)(V !7FNI_';P[:7)BLK2\OT!_UJ (I^F[D_E7GWB_7]8^)_C(:-HZM
M)912%+:('"G'!E<^G\A]:]"T'X*^'-*LA-KKG4+@#=(SN8XD^@';W)KG5&E2
MBG5W?1'I;;EG0OC7X9U:=8+P3Z9*QPIN #&3_O#I^->C(Z2(KQLK(PRK*<@C
MU%>/ZGX(^&NO3FQTJ]2POV^6-H'8HS>F&X/X&D^'^I:SX*\2R^!]>!ECD0RZ
M=(&^5L<[4)[$9X[$8I5*$&KPNGV?;R(C.$U>+N>QT56LKZWU"%I+=\[6*.I&
M&1AU!'8T:C?0Z9IUQ?7!Q%!&7;\.U<G*[VZCYE:_0BU76=/T6U^T:C=1P1]!
MN/+'T ZFN1E^+.A)*5C@O9$_OB,#]":\OU"_U/Q=KPD97FN9WV0PKT0=E'H!
MW-=G:_"&[>U#76JQQ3D9\M(MR@^A.17I_5*%&*]O+5GG_6:U5OV*T.[T3QCH
MFOOY5E=@3XSY,HV/^ /7\*WJ^=M>\/:GX5U*..Y^5L[X+B(D!L=P>Q'I7K_@
M/Q*_B/0LW)!O;9O+F(_B]&_$?J*QQ.%C"*J4W>)M0Q+G+V=16D=51117"=85
M\Z:I_P CC=_]?Y_]#KZ+KYTU3_D<;O\ Z_S_ .AUZ>6[S]#@Q^T?4]\ULD:!
MJ)!P1;2?^@FO#_A_$LOC72PR[@K,WXA2<U[AKG_(OZC_ ->LG_H)KQ3X<?\
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MB.1&IP /J<G\JSO'?B:\U[6)-'T_S7LX&V%(@29G'4G'4 \"NC^%-WGX60*
M5GL_/BD7NKJQ./U%:W@#3K2Q\*6]\ GGW2F:>8]3DGC/H*TC55.I.M)7:=E_
M7H9XRG.LU1B[)ZOT['E>E>$->N]1MT73;F$;U)ED0HJ 'KDUZ'\3[)(]/T;6
MDP+S3=2MVCDQR59PK+^.0?PJK>?&WPA:W$L,;WMR8R5#PP95B/0DCBN3;QG>
M?%/QEI&BV5DUMI%O<K=SAVR[K&<Y;' &> /4U56I6K24YQLD5A,''#)J+O<]
M"\1W'_"-^(M/UJ,[;:\<6MZ@Z-_<?ZCG\*3XGSM%X*F53Q++&A^F<_TJM\5Y
MD3PK#&3\[W*[?P!)J#Q^[2_#:QD?[[- 3]=M12A?V4WWM]VQE.=I5::[)_?N
M8?PCLHY=8OKQP"\$2HF>VX\G\A7KU>5?!_\ U^K?[L?_ +-7JM9X]WKOY&V#
M5J*.0^)=E%=>#+F5U&^V994;N#D _H:XWX1SLGB"^@S\DEL&(]PP_P 37=_$
M'_D1M3_W%_\ 0A7G_P )O^1IN/\ KU/_ *$*WH:X.:?];&5;3%0?]=3V:BBB
MO,.\*^=-4_Y'&[_Z_P _^AU]%UXW?_#[Q'/XCN+R.UA,#W9E4F=<[=V>GTKT
M,!4A!RYG;0XL;"4E'E5]3U77/^1?U'_KUD_]!->*?#C_ )'?3O\ =D_] ->W
MZI!)=:1>6\0!DE@=$!.,DJ0*\Q\&>!M?T;Q197U[;1);Q!P[+,K$94CH*6%J
M1C1J)O5_Y!B(2E5@TMCUFO+/C#]_2/\ MK_[+7J=<'\1O#.J^(FT\Z;"DGD[
M]^Z0+C.,=?I6.#DHUHN3LC7%1<J321+\*O\ D3C_ -?4G]*[>N7\!:-?:%X<
M^QZA&L<_GN^%<,,'&.1745&):E6DUW+H)JE%/L?.?_,X_P#<1_\ :E>[>*/^
M15U7_KUD_P#037F!^'WB,^(_MGV2+R/MGFY\]<[=^<X^E>JZY:S7V@W]K H:
M::!T0$X!)''-=F,J0E*FXN]O^ <N%IRC&=UO_P $\8^&O_(\67_7.3_T&O=Z
M\I\$^"->T7Q1;7U];1);HCAF696()7 X%>K5GF$XSJWB[Z&F"A*-.TE;4\F^
M+_\ R$=+_P"N3_S%=1\,/^1)M_\ KM)_Z$:H?$7PMJ_B&\L)--@CD6&-U<M(
M%P21CK6YX&TB]T/PQ%97\:QSK([$*P88)R.155*D'A(Q3UO_ )DPA)8F4K:?
M\,=)7SKIG_(Z6G_81'_HROHJO&['X?\ B.'Q)!>O:Q"!+P2EO/7.W?G./I1@
M:D8*?,[77^88N$I.'*KZ_P"1ZQJUBNIZ1=V+=)XF3/H2.*^?M(U"[\+>(X[E
MHSY]I(4FB/&1T85]&UQ/C/P!%X@D-_8R+;ZAC#;A\DN/7T/O4X.O&%Z=3X65
MBJ,IVG#='0:7XFT?5[1;BUOX<$99'<*R>Q!Z5QGQ"\;61TR71],G6>>?Y9I(
MSE47N,]R:X:Y\"^);:8HVD32'^]%AP?Q%:FC?#'6]0E4WR+86V?F+D%\>RC^
MM=$</AJ<O:.=TC"5>O4CR*%F7?A1I+W&MSZHRGR;:,QJW8NW^ _G71?%O_D6
MK7_KZ'_H)KL=(TFTT338K"RCV0QC\6/<D]R:Y_XA:%J&OZ+;VVG1+)*EP'8,
MX7C!'4_6L%B%4Q2J/1&WL7##N"U9B?!__D':K_UW3_T&O2:XKX=>'=3\/6=_
M'J4*1M-*K)MD#9 &.U=K6.+DI5I.+NC7#1<:23.2&BR>'/$-YJ.GPM+I6J'=
M?6R#+12]/-0=P1PP^A%8?AN_CMEU3P3J$WDEO,2SF/ 9'!P![\Y%>DUR7C/P
M7'XEA6YMW6'481A'/1Q_=/\ 0]J=&I%WA4V?7LULR<3&II4I:M=.ZZH\1C^#
M/C$ZH;+[+;K"IQ]K:8>65]<=?PQ7M?@WP7I7P_T>5C,KW#KNNKV7"Y [#T4>
ME<1_;?CSPV/LLZ7#HO"M+#YH_!AUJC-_PF/C&9898[N://W2GE1+[GH*[YT*
MM5>_.*CW1RRS-6Y8PES=K%SQ!JTGCSQ=9Z?8AOL:/LCSW'\3G\!78?%"-8O!
M*1H,*EQ$H'L,U>\&>"X?#,#3S,LVH2KAY .$']U?\>]2>/=&OM=\-_8]/C62
M?ST?#.%&!G/)KGE7I^VIQA\,?Z;'2H5%2G.I\<OZ2.1^#_\ K]6_W8__ &:O
M5:X+X=>&-5\.RZ@VI0I&)@@3;(&SC.>GUKO:PQDHRK-Q=T=6%BXTDFCF?B#_
M ,B-J?\ N+_Z$*\_^$W_ "--Q_UZG_T(5Z7XNTZZU;PM?6-FBO<2J BLP4'Y
M@>IKD/A_X0UK0->FNM1MXXX6MR@*RAN<@]OI6U&I%86<6]7_ , RJPD\1"26
MAZ51117GG:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% %>XOK2UF@AN+F**2=ML2.X!D/H!W/(JQ7#>./^1K\'_\ 7\?YI7<UI."C
M&,N_^=B(SO*2[?Y%>XOK2UF@AN+F**6=ML2.X!D/H!WZBH[W5M.TYXTO;ZWM
MFD^X)9 I;Z9^M<EXW_Y&SP?_ -?I_FE9WQ&L/[4\4:!8YP9TF4'WP"/U K:G
M0C)QN]TW]QE.M**E9;-?B>E53?5M.COUL'OK=;QL 0&0!SGD<=:I^%M1.I^&
M+"Z<_O/*"2Y/1U^5L_B#7FT.Z\^(.C:RV<:A?S&//_/-/D7^M*E0YG)2=K7^
M_7_(=2MRJ+74]9^WVGV[[#]IA^U[-_D;QOV^N.N*JW'B'1K6=X+C5;.*9#AT
M>=0RGW&:Y9O^2TK_ -@W^M;.I>"O#M_<7%]=::LES+EW?S'&3CT!QVI.G3BU
MSMZI/2PU.<D^5+1V+G_"4Z!_T&K#_P "%_QJ>YUO2[-(7N=1M85F7?$9)54.
MOJ,GD<BO/?A_X2T/6_#/VO4;!9Y_/=-Y=AP,8'!%6O&.F64WB_PGIDL(-EL>
M(QEB!L &!G.>PK5T*7M?9IO2]]NB,U6J>SYVEK;OU.Q_X2C0/^@U8?\ @0O^
M-6TU2PDL&OTO;=K-<YG$@V#!P>>E8'_"O_"/_0,B_P"_S_\ Q5,\3:99:1\.
M=4L]/A$5LL+%4#$\ELGDD]ZRY*4FHQ;U?6QIS5$FY):+S-<>*- ) &LV&3_T
M\+_C6G#-%<1B2&5)$/1D8$'\17#^'/ WAN_\-:==7.FJ\\UNCR/YCC+$<G@U
M7BT__A!O&EA#8RO_ &3JS&(V[-GRY!T(_P ]S52I4VW&#=U??R)52:2E)*S[
M>9Z'1117*= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 <-XW_P"1K\'_ /7\?YI7<URGC'PUJ.O7&EW&F7D-K-8NT@>0$\G;@C /
MI64?#OQ P<>*K?/_ %S_ /L:Z^6%2G%<R5K[W[^AS<TH3E[K=_\ (G\;_P#(
MV>#_ /K]/\TIOBS_ )*)X2_WY/Z5J:QX<O=4U#P[=_:8=VFRB2<L#F0_+G;C
M_=-2:UX=N=3\4Z)JL4T21:>SF1&SN;..E5"I!<MWLI?C<4H2?-INU^AS[WS>
M'-/\7:<G#1R>=:J/2?@8^C9JO?Z<ND^)_ E@H_U",I^N!G]<UT.O>$7UCQ1I
MFJ+.B008^T1'.90K;E^O/K4^M>';G4_%.B:K%-$D5@SF1&SN;/I3C5AH[[IW
M];6_KU$Z<M=-FK>E[F.W_):%_P"P;_6NXF_U$G^Z?Y5SY\.W)\?#Q!YT7V<6
MGD>7SOSGKZ8KH9%WQLHZD$5A6DI<MNB1M3BUS7[LXKX5?\B;_P!O4G]*H>/M
M/BU;QEX;T^=G6*X$B,4.& X/'Y5TO@SP_<>&M!^P7,T4LGG/)NBSC!QZU1\7
M>%]4UO5=-U#2[Z"TFLU?#R D@G'(X/O6ZJ1^LRFG9:Z_(Q<)>P4;:Z:?,I?\
M*FT'_GZU'_OZO_Q-7_$FFPZ/\,[[3[=I&A@M2BF0Y8C/<UF_\([\0/\ H:K?
M_OW_ /8UJ?\ "/Z[=^#M1TG5-3ANKVYR(Y]N%5>, X [@_G1*<KQ<ZB:37?_
M "!15FHPM=/^MS1\(?\ (GZ1_P!>D?\ Z"*P/&FR]\6>%M.0DS+=&=E7JJ#!
MS^AJI:^%/'-G;16L'B:WC@B4(B+'G:H[#*UN^'?" TB_EU2_OI-0U24;3/(,
M!5] *E\E.;J*2>]K7ZW_ ,Q^_.*ARVV_ Z>BBBN,Z@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  = %X# 2(  A$! Q$!_\0
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1@ #DGIWHG*FT^4<%/2Y__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
